Suthee Rapisuwon MD

Genitourinary Oncology, Melanoma

Assistant Professor

110 Irving St NwSuite C2149Washington, DC 20010
Phone+1 202-687-8901
Fax+1 202-444-8829

Dr. Rapisuwon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rapisuwon's full profile Already have an account?

Summary

Dr. Suthee Rapisuwon is an oncologist in Washington, DC and is affiliated with multiple hospitals in the area, including MedStar Georgetown University Hospital and MedStar Washington Hospital Center. He received his medical degree from Mahidol University Faculty of Medicine and has been in practice 14 years. He specializes in genitourinary oncology and melanoma and is experienced in malignant melanoma, mucosal melanoma, clinical genetics, cutaneous malignant melanoma, and uveal neoplasms.

Education & Training

MedStar Health Georgetown UniversityFellowship, Hematology and Medical Oncology, 2012 - 2015
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine/Medical Genetics and Genomics, 2007 - 2012
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Medical Genetics and Genomics, 2007 - 2012
Mahidol University Faculty of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 2022 - 2027
DC State Medical License 2012 - 2026
OH State Medical License 2007 - 2013
American Board of Internal Medicine Medical Oncology
American Board of Medical Genetics and Genomics Clinical Genetics and Genomics

Clinical Trials

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab Start of enrollment: 2017 Jul 26
Terminated
Phase 2
Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Start of enrollment: 2018 Jul 26
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.
Suthee Rapisuwon, Craig L Slingluff Jr, Jennifer A Wargo, Ryan J Sullivan, Benjamin Izar
Cancer Medicine. 2026-01-01
Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus.
Juan Alban, R Christopher Bowen, David A Reichstein, Meredith McKean, Jose Lutzky
Cancers. 2025-12-30
1 citations
Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.
Kylie A Fletcher, Rachel S Goodman, Aleigha Lawless, Rachel Woodford, Faisal Fa'ak
JAMA Dermatology. 2025-05-01

Lectures

Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
2019 ASCO Annual Meeting - 6/1/2019
Identification of a gene expression signature predictive of clinical benefit in patients with advanced mucosal melanoma (MCM) treated with immune checkpoint blockade.
2019 ASCO Annual Meeting - 6/1/2019
Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): I...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018